Status:

COMPLETED

Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.

Lead Sponsor:

Biodel

Conditions:

Type 2 Diabetes

Eligibility:

All Genders

40-75 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to compare the effects of insulin VIAject with Regular Human Insulin and Insulin Lispro on measures of mealtime blood vessel stress and blood flow.

Eligibility Criteria

Inclusion

  • Type 2 diabetes mellitus according to the ADA criteria
  • HbA1c between 6.5 % and 9.9 %
  • Treatment with sulfonylurea and/or metformin in a stable dosage within the last 3 months
  • Age between 40 and 75 years
  • BMI \< 40

Exclusion

  • Type 1 diabetes mellitus
  • Pre-treatment with insulin within the last 6 months prior to screening
  • Pre-treatment with PPARy-agonists or glucosidase inhibitors within the last 4 weeks prior to screening
  • Untreated hypertension stage II-III according to WHO criteria
  • Planned or anticipated change in antidiabetic and/or concomitant medication during study participation
  • Total cholesterol \> 300 mg/dl (anamnestically)
  • Major micro- or macrovascular complications as judged by the investigator
  • Tobacco use within the last 6 months prior to screening
  • Drugs with major impact on endothelial function like nitrates etc.
  • History of drug or alcohol abuse which in the opinion of the investigator will impair subject safety or protocol compliance
  • History of hypersensitivity to the study drugs or to drugs with similar chemical structures
  • History of severe or multiple allergies
  • Treatment with any other investigational drug within 3 months prior to screening
  • Progressive fatal disease
  • History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT \> 3 times the normal reference range), renal (creatinine \> 1.1 mg/dL in women and \> 1.5 mg/dL in men), neurological, psychiatric and/or haematological disease as judged by the investigator
  • Pregnancy or breast feeding
  • Sexually active women of childbearing potential not consistently and correctly practicing birth control by implants, injectables, oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner
  • Lack of compliance or other similar reason that at the discretion of the investigator precludes satisfactory participation in the study
  • Hypopotassemia (K\<3.5 mmol /l)

Key Trial Info

Start Date :

April 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2008

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00849576

Start Date

April 1 2008

End Date

August 1 2008

Last Update

August 3 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

IKFE

Parcusstrasse 8, Mainz, Germany, 55116